See more : Hartshead Resources NL (PGNYF) Income Statement Analysis – Financial Results
Complete financial analysis of GH Research PLC (GHRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GH Research PLC, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sumavision Technologies Co.,Ltd. (300079.SZ) Income Statement Analysis – Financial Results
- The PMI Group, Inc. (PMIR) Income Statement Analysis – Financial Results
- Actic Group AB (publ) (ATIC.ST) Income Statement Analysis – Financial Results
- IMV Inc. (IMVIF) Income Statement Analysis – Financial Results
- Lasa Supergenerics Limited (LASA.NS) Income Statement Analysis – Financial Results
GH Research PLC (GHRS)
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 315.00K | 47.00K | 19.00K | 0.00 | 0.00 |
| Gross Profit | -315.00K | -47.00K | -19.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.79M | 20.48M | 8.55M | 338.00K | 296.00K |
| General & Administrative | 11.30M | 10.07M | 6.55M | 108.00K | 14.00K |
| Selling & Marketing | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.12M | 10.07M | 6.55M | 108.00K | 14.00K |
| Other Expenses | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Cost & Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Interest Income | 1.89M | 858.00K | 9.00 | 0.00 | 0.00 |
| Interest Expense | 723.00K | 0.00 | 9.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 315.00K | 47.00K | 19.00K | 446.00K | 310.00K |
| EBITDA | -41.15M | -30.63M | -15.08M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -41.22M | -30.55M | -15.10M | -446.00K | -310.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.64M | 8.10M | 5.90M | 0.00 | 0.00 |
| Income Before Tax | -35.59M | -22.46M | -9.20M | -446.00K | -310.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.32M | 9.00K | -205.30K | -310.00 |
| Net Income | -35.59M | -7.14M | -9.21M | -446.00K | -310.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| EPS Diluted | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
| Weighted Avg Shares Out (Dil) | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and...
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided...
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO)...
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 488.7% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
GH Research Reports Third Quarter Financial Results and Provides Business Updates
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and...
New Strong Buy Stocks for October 25th
RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its...
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and...
The 3 Best Psychedelic Stocks to Buy Now
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health...
Source: https://incomestatements.info
Category: Stock Reports